Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma

Source: OncLive, September 2020

Mattia Garutti, MD, medical oncologist, Unit of Clinical Oncology, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, discusses the potential shift to neoadjuvant therapy in melanoma.

Patients with stage III melanoma have a high risk of relapse, says Garutti. As such, developing new therapies to increase the rates of cure among patients is a critical area of research.

Moreover, the potential shift from adjuvant therapy to neoadjuvant therapy may usher in a new era of melanoma management, Garutti explains.

READ THE ORIGINAL FULL ARTICLE